As part of our response to the coronavirus outbreak, we
have decided to conduct only essential Good Practice
(GxP)
inspections of Laboratories, Clinical Trials,
Manufacturing, Distribution and Pharmacovigilance until
further notice.
Other MHRA inspections will be deferred to a later
date.
Our Good Practice inspections monitor compliance with
the MHRA’s UK standards in sites engaged in laboratory
studies, clinical trials, manufacturing, distribution,
and pharmacovigilance (safety monitoring of medicines).
They are conducted both in the UK and overseas.
We are expecting organisations to
maintain GxP compliance,
and will support the industry and NHS to focus on
service continuity by using alternative approaches for
routine regulatory oversight, such as office-based
assessment and the sharing of information within the
international regulatory network.
We will prioritise essential on-site inspections linked
to the UK Government’s COVID-19 response or any other
potential serious public health risk, where these sites
cannot be assessed remotely. Essential clinical trial
authorisation applications will not be affected by this
change and will remain prioritised.
We understand current challenges, and are acting in
line with UK Government recommendations to minimise the
impact of any such inspections on industry and agency
personnel wherever possible.
This situation remains under review and we will provide
further information as it becomes available.
If you have any questions on GxP-related issues,
please email: